Why the Liver Dominates Nucleic Acid Therapeutics
The liver is the primary organ of interest across RNAi, gene editing, and epigenetic modality classes because of three converging properties: its anatomical accessibility via systemic circulation, its central role in synthesising key circulating proteins and lipids, and its amenability to lipid nanoparticle-mediated nucleic acid delivery. No other organ offers this combination of biological relevance and delivery tractability at clinical scale.
The disease focus is correspondingly broad: metabolic liver disease (NAFLD, NASH), viral hepatitis (HBV), inherited metabolic disorders (acute hepatic porphyria, transthyretin amyloidosis, primary hyperoxaluria), and dyslipidaemia (PCSK9-driven hypercholesterolaemia, LPA-linked cardiovascular disease). What unites them is that the causative gene or the primary site of pathological protein production is the hepatocyte — making targeted silencing in liver cells a direct therapeutic intervention rather than a downstream symptomatic approach.
Patisiran, an siRNA targeting transthyretin (TTR) mRNA, achieved 87% hepatic transthyretin knockdown in patients with transthyretin amyloidosis, with knockdown lasting several weeks after a single dose.
According to WIPO patent data, nucleic acid therapeutics have been among the fastest-growing patent filing categories in the life sciences over the past decade — and the liver-targeted segment represents a disproportionate share of that activity. This is reflected in the patent dataset analysed here, where innovation signals span jurisdictions including Japan, Australia, China, Taiwan, South Korea, Spain, and India, with assignees ranging from US biotechnology leaders to emerging Asian pharmaceutical developers.
Therapeutic Modalities: From RNAi to Epigenetic CRISPR
RNAi-based approaches constitute the most represented modality in the liver-targeted gene silencing patent landscape, but the field is not monolithic. At least six distinct mechanistic classes appear in the retrieved dataset, each with a different risk-benefit profile for hepatic applications.
RNAi (siRNA, DsiRNA, shRNA)
Double-stranded RNA agents targeting mRNA degradation via RISC-mediated cleavage are the dominant modality. Multiple filings describe chemically modified siRNA molecules — incorporating 2′-O-methyl, 2′-fluoro, and phosphorothioate backbone modifications — to improve stability, reduce off-target effects, and enhance pharmacokinetics. Alnylam Pharmaceuticals is the most frequently represented assignee across jurisdictions (KR, ES, IN, JP), with patents spanning PNPLA3, ALAS1, and foundational dsRNA gene silencing methods. Dicerna Pharmaceuticals, Arrowhead Pharmaceuticals, Beijing Winsunny Pharmaceutical, Suzhou Ribo Biotechnology, and Silence Therapeutics each contribute distinct target-specific RNAi IP.
DsiRNA molecules are longer double-stranded RNA constructs (typically 25–27 nucleotides) designed to be processed by the Dicer enzyme before loading into RISC, potentially improving potency compared with standard 21-nucleotide siRNA. Dicerna Pharmaceuticals’ patent describes LNP-formulated DsiRNA targeting LDHA for in vivo hepatic delivery, with noted in vivo tolerability data.
LNP-Delivered CRISPR/Cas9 Genome Editing
LNP platforms for systemic in vivo delivery of Cas9 mRNA and guide RNA represent the most clinically advanced gene editing approach in this dataset. Intellia Therapeutics’ 2023 Australian patent explicitly describes the first systemic CRISPR/Cas9 clinical administration via LNP, targeting TTR in transthyretin amyloidosis, with greater than 60–80% serum prealbumin reduction as the efficacy threshold. Acuitas Therapeutics describes LNP formulations comprising cationic lipids for delivery of engineered nuclease mRNAs. Harvard College and the Broad Institute describe CRISPR-Cas system delivery for liver target sequences, noting NHEJ for knockdown and HDR for therapeutic correction.
Epigenetic CRISPR Silencing (CRISPRi)
Tune Therapeutics’ patent describes a CRISPR-Cas/gRNA system for transcriptional repression rather than DNA cleavage, targeting LDL-regulatory genes including multiplexed repression of multiple genes simultaneously. This represents an emerging distinction: durable hepatic gene silencing without permanent genomic modification, which may reduce regulatory complexity compared with nuclease-based editing.
Engineered Meganucleases
Precision BioSciences describes engineered meganucleases — large single-chain endonucleases distinct from CRISPR — with specificity for HBV genomic recognition sequences, including suicide gene knock-in strategies following HBV genome cleavage for treating HBV infection and hepatocellular carcinoma.
Explore the full patent landscape for liver-targeted gene silencing modalities in PatSnap Eureka.
Search Patents in PatSnap Eureka →Key Molecular Targets and Clinical Signals
The most clinically advanced hepatic gene silencing targets in this dataset are TTR and PCSK9, both of which have progressed to human trials. PNPLA3, HBV, and LPA represent the most active preclinical-to-translational tier, with multiple independent assignees filing competing IP.
Inclisiran, an siRNA targeting PCSK9 mRNA, demonstrated durable PCSK9 suppression and serum cholesterol reduction for six months from a single dose in a phase I clinical trial, establishing PCSK9 as the benchmark validated systemic RNAi target for LNP-liver delivery.
TTR (Transthyretin): Intellia Therapeutics’ LNP-CRISPR data describe clinical-stage TTR reduction via systemic administration, with dosing strategy including re-dosing thresholds based on serum prealbumin levels. Separately, patisiran (an anti-TTR siRNA) achieved 87% hepatic transthyretin knockdown in patients with transthyretin amyloidosis, lasting several weeks after a single dose. TTR is the most clinically advanced hepatic gene editing target in this dataset.
PCSK9: Referenced in both a clinical literature record (inclisiran, phase I, six-month cholesterol suppression) and a CSPC Zhongqi Pharmaceutical patent on modified dsRNA inhibiting PCSK9 expression, PCSK9 is the benchmark validated systemic RNAi target for liver delivery. A single siRNA dose efficiently suppressed serum cholesterol for six months in the phase I inclisiran trial.
PNPLA3: Three independent assignees — Alnylam Pharmaceuticals, Amgen, and Wave Life Sciences — have separately filed RNAi or ASO patents targeting PNPLA3 for NAFLD/NASH. Amgen’s patent describes selective inhibition of the rs738409 risk allele over the reference allele, signalling a precision medicine direction that restricts silencing to the disease-predisposing variant. IP crowding is a risk for new entrants in this target space.
“A single siRNA dose efficiently suppressed serum cholesterol for six months in the phase I inclisiran trial — positioning hepatic RNAi delivery as the established, feasible clinical frontier for nucleic acid therapeutics.”
HBV genome: Three distinct patent clusters address HBV-infected hepatocytes: RNAi triggers from Arrowhead Pharmaceuticals (with primate safety data including AST, ALT, BUN, creatinine), siRNA conjugates from Suzhou Ribo Biotechnology, and engineered meganucleases from Precision BioSciences including suicide gene insertion strategies for HBV-infected hepatocyte elimination.
LPA (Lipoprotein(a)): Both Dicerna Pharmaceuticals and Silence Therapeutics have filed RNAi agents targeting liver-expressed LPA, with target diseases spanning cardiovascular risk, NAFLD, and NASH. Active parallel IP development in this space suggests competitive pressure is building.
ALAS1: Alnylam Pharmaceuticals’ patent describes dsRNA compositions for ALAS1 inhibition in acute hepatic porphyria, a liver-specific metabolic disorder in which the causative enzyme is exclusively hepatocyte-expressed.
LDL-regulatory gene network: Tune Therapeutics describes multiplexed CRISPR-based epigenetic silencing of multiple LDL-regulatory genes simultaneously — including PCSK9 and ANGPTL genes — signalling interest in combinatorial chromatin-level hepatic gene repression as a cardiovascular metabolic strategy.
Delivery Platforms: LNP vs. GalNAc Conjugates
LNP delivery is the most clinically validated platform for hepatic nucleic acid therapeutics in this dataset, confirmed by clinical-stage LNP-CRISPR (Intellia/TTR) and clinical-stage LNP-siRNA (inclisiran/PCSK9, patisiran/TTR). However, GalNAc-siRNA conjugates are emerging as the primary non-LNP delivery strategy for hepatic RNAi, and the two platforms represent distinct but converging IP clusters.
Intellia Therapeutics’ 2023 Australian patent describes the first systemic administration of a CRISPR/Cas9-based therapeutic for in vivo liver editing in a clinical trial, delivering Cas9 mRNA and a TTR-targeting guide RNA as a lipid nanoparticle formulation, with greater than 60–80% serum prealbumin reduction as the clinical efficacy threshold.
Several siRNA patents in this dataset — from Suzhou Ribo Biotechnology, Silence Therapeutics, Beijing Winsunny Pharmaceutical, and Wave Life Sciences — describe siRNA-ligand conjugates for hepatocyte-directed delivery. Silence Therapeutics explicitly describes GalNAc-type targeting ligands positioned at 3′ and 5′ termini of RNA strands. GalNAc (N-acetylgalactosamine) exploits the asialoglycoprotein receptor (ASGPR), which is highly and selectively expressed on hepatocytes, enabling receptor-mediated endocytosis of conjugated siRNA without the need for a lipid carrier.
Academic and commercial groups pursuing LPA, HSD17B13, DGAT2, and PCSK9 are split between LNP and GalNAc-conjugate platforms. Organisations controlling both formulation and conjugation IP — or licensing both — will have stronger freedom to operate. New entrants should assess clearance across both delivery modality patent families before committing to a single platform strategy.
AAV-based delivery for liver-targeted RNAi expression cassettes is represented by UniQure IP B.V., whose synthetic liver-specific promoters outperform the LP1 promoter by up to 50-fold in liver-specific transgene expression in AAV vectors (validated in Huh7 cells and animal models), with corresponding suppression in non-hepatic cells. This level of hepatic specificity is directly relevant to RNAi expression cassette delivery where off-target tissue expression would be undesirable.
The academic literature record in this dataset, from Hannover Medical School, notes that siRNA delivery beyond the liver remains a clinical limitation — reinforcing the liver’s position as the primary tractable organ for systemic nucleic acid delivery, as noted in publications indexed by NIH PubMed.
Track LNP formulation and GalNAc conjugate patent filings across assignees with PatSnap Eureka.
Explore Delivery IP in PatSnap Eureka →Assignee Landscape and IP Concentration
Innovation activity in this dataset is predominantly patent-driven, with most assignees being biotechnology or pharmaceutical companies. Alnylam Pharmaceuticals is the most frequently represented assignee for liver-targeted RNAi, with patents spanning PNPLA3, ALAS1, and foundational dsRNA gene silencing methods across multiple jurisdictions including South Korea, Spain, India, and Japan.
The assignee landscape reveals a clear geographic and strategic distribution. US biotechnology leaders (Alnylam, Intellia, Arrowhead, Dicerna, Precision BioSciences, Tune Therapeutics, Amgen) dominate the clinical and near-clinical tier. European innovators (Silence Therapeutics, UniQure, Mina Therapeutics, Alnylam Europe AG) contribute platform and delivery IP. Asian pharmaceutical developers (Beijing Winsunny Pharmaceutical, Suzhou Ribo Biotechnology, CSPC Zhongqi Pharmaceutical) are active in metabolic liver disease and HBV siRNA conjugate development, primarily in Taiwan and China jurisdictions — signalling commercial development interest in these markets independent of Western clinical pipelines.
Alnylam Pharmaceuticals is the most frequently represented assignee for liver-targeted RNAi in the retrieved patent dataset, with filings spanning PNPLA3, ALAS1, and foundational dsRNA gene silencing methods across jurisdictions including South Korea, Spain, India, and Japan.
Academic institutions are sparsely represented. The primary academic contributions are the Hannover Medical School literature record on LNP-delivered RNAi, a Harvard College/Broad Institute patent on CRISPR-Cas liver delivery, and a University of North Carolina patent on reverse chimeric siRNA molecules for dual inhibition of c-Myc and KRAS with improved serum stability over tandem chimeras. According to EPO data, academic-to-industry patent transfer in the nucleic acid therapeutics space has accelerated since 2018, consistent with the predominantly commercial assignee composition observed here.
Notable structural innovation signals include Guangzhou Ribobio’s patent on polymeric nucleic acid units enabling multi-target interference from a single construct, and the University of North Carolina’s reverse chimeric siRNA approach — both suggesting that siRNA architecture optimisation remains an active area of IP development alongside target and delivery innovation. Standards bodies such as ISO are also developing guidance frameworks for nucleic acid therapeutic characterisation that will influence how these innovations are assessed for regulatory submission.
Strategic Implications for Drug Discovery Teams
The patent landscape for liver-targeted gene silencing reveals five strategic dynamics that drug discovery teams and IP professionals should monitor closely.
LNP delivery IP remains a critical competitive space. IP strategies targeting LNP formulation composition and delivery optimisation are directly relevant to any hepatic nucleic acid programme. Acuitas Therapeutics’ LNP formulation patents and Intellia’s clinical LNP-CRISPR IP represent key freedom-to-operate considerations for any team working in this space.
PNPLA3 is an emerging high-activity target with IP crowding risk. With at least three independent assignees — Alnylam, Amgen, and Wave Life Sciences — filing RNAi or ASO patents for PNPLA3 in this dataset, new entrants face a crowded IP landscape. Allele-selective approaches targeting the rs738409 risk variant may offer differentiation, but the allele-selective strategy itself is now claimed by Amgen.
HBV shows multi-modality convergence. RNAi triggers (Arrowhead, Suzhou Ribo) and engineered meganucleases (Precision BioSciences) are being pursued in parallel for the same infected-hepatocyte indication. Combination regimens are not yet explicitly documented in the retrieved results but represent a logical next step given the single-agent limitation of viral suppression.
CRISPRi may reduce regulatory complexity vs. nuclease editing. Tune Therapeutics’ filings for transcriptional repression rather than DNA cleavage signal a strategic differentiation play worth monitoring, particularly for cardiovascular metabolic targets like LDL where permanent genomic modification may face additional regulatory scrutiny.
saRNA (short activating RNA) represents a mechanistically distinct opportunity. Mina Therapeutics’ patent on saRNA upregulating albumin production by activating albumin, CEBPA, or HNF4a — for cirrhosis, hepatitis, and liver cancer — represents a gene activation rather than silencing approach. This mechanistic contrast with the dominant silencing modalities suggests potential for combination strategies or distinct IP positioning.
For teams conducting freedom-to-operate analysis or target prioritisation in liver-directed gene therapy, the PatSnap IP intelligence platform provides cross-jurisdictional patent mapping across all modalities and assignees discussed in this analysis. The PatSnap R&D intelligence module enables target landscaping across both patent and literature sources simultaneously.